Insulet Corporation $PODD Shares Purchased by Janney Montgomery Scott LLC

Key Points

• Janney Montgomery Scott LLC increased its stake in Insulet Corporation by 784.9%, owning a total of 47,827 shares valued at approximately $15.03 million.
• Insulet reported a quarterly earnings per share of $1.17, exceeding expectations and showing a 32.9% year-over-year revenue growth.
• Several analysts have raised their target prices for Insulet's stock, with Canaccord Genuity setting a new target of $399.00 and maintaining a "buy" rating.

Janney Montgomery Scott LLC boosted its holdings in Insulet Corporation (NASDAQ:PODD - Free Report) by 784.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 47,827 shares of the medical instruments supplier's stock after acquiring an additional 42,422 shares during the period. Janney Montgomery Scott LLC owned 0.07% of Insulet worth $15,026,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the business. Nissay Asset Management Corp Japan ADV boosted its stake in shares of Insulet by 0.6% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier's stock worth $2,222,000 after purchasing an additional 48 shares during the last quarter. Mather Group LLC. boosted its position in shares of Insulet by 4.4% in the second quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier's stock worth $360,000 after acquiring an additional 48 shares during the last quarter. Brooklyn Investment Group boosted its position in shares of Insulet by 7.0% in the first quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier's stock worth $209,000 after acquiring an additional 52 shares during the last quarter. OLD National Bancorp IN boosted its position in shares of Insulet by 6.7% in the first quarter. OLD National Bancorp IN now owns 880 shares of the medical instruments supplier's stock worth $231,000 after acquiring an additional 55 shares during the last quarter. Finally, Cooper Financial Group boosted its position in shares of Insulet by 5.7% in the first quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier's stock worth $283,000 after acquiring an additional 58 shares during the last quarter.

Insider Buying and Selling

In other news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.39% of the company's stock.

Insulet Trading Up 2.0%

PODD opened at $312.21 on Friday. The firm has a market capitalization of $21.98 billion, a P/E ratio of 94.90, a P/E/G ratio of 2.54 and a beta of 1.40. The firm's 50 day moving average is $320.96 and its 200-day moving average is $298.20. Insulet Corporation has a 52-week low of $225.37 and a 52-week high of $353.50. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. The company had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business's quarterly revenue was up 32.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Analysts expect that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on PODD shares. Canaccord Genuity Group raised their target price on shares of Insulet from $353.00 to $399.00 and gave the stock a "buy" rating in a research report on Monday. Piper Sandler raised their target price on shares of Insulet from $320.00 to $360.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 16th. Wall Street Zen raised shares of Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Truist Financial initiated coverage on shares of Insulet in a research report on Monday, June 16th. They issued a "buy" rating and a $365.00 target price on the stock. Finally, Oppenheimer raised their price target on shares of Insulet from $324.00 to $365.00 and gave the company an "outperform" rating in a report on Monday, September 8th. Sixteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $345.47.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.